| scholarly article | Q13442814 |
| P50 | author | Kevin J Horgan | Q56797386 |
| P2093 | author name string | Ronald de Wit | |
| Juliana Ianus | |||
| Richard J Gralla | |||
| Alexandra D Carides | |||
| Judith K Evans | |||
| Jorn Herrstedt | |||
| Julie Guoguang-Ma | |||
| P2860 | cites work | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr | Q33190512 |
| Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology | Q33880234 | ||
| Chemotherapy-related nausea and vomiting: etiology and management | Q38222097 | ||
| Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists | Q40655344 | ||
| Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies | Q40855095 | ||
| Serotonin mechanisms in chemotherapy-induced emesis in cancer patients | Q41023026 | ||
| The severity and pattern of emesis following different cytotoxic agents | Q41023032 | ||
| Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis | Q41023054 | ||
| Proposal for classifying the acute emetogenicity of cancer chemotherapy | Q41314646 | ||
| Drug treatment of chemotherapy-induced delayed emesis | Q41445456 | ||
| Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs | Q42371534 | ||
| Reduced maintenance of complete protection from emesis for women during chemotherapy cycles | Q44308882 | ||
| Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. | Q44433152 | ||
| Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America | Q44464294 | ||
| The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St | Q44618271 | ||
| Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. | Q50980250 | ||
| Why Do We Need Another Antiemetic? Just Ask | Q59566139 | ||
| Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients | Q61823020 | ||
| Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model | Q61900681 | ||
| The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy | Q70105967 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| P304 | page(s) | 864-868 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran | |
| P478 | volume | 104 |
| Q26784064 | A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting |
| Q50769042 | A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. |
| Q86643798 | A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies |
| Q34013540 | A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting |
| Q28070085 | Acupuncture: could it become everyday practice in oncology? |
| Q38208999 | Anticipatory nausea in animal models: a review of potential novel therapeutic treatments |
| Q45980917 | Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. |
| Q43286569 | Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial |
| Q37355479 | Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. |
| Q34637875 | Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study |
| Q41103220 | Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. |
| Q37589613 | Aprepitant: a review of its use in the prevention of nausea and vomiting |
| Q34450534 | Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. |
| Q38098277 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia |
| Q42642028 | Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. |
| Q39275766 | Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. |
| Q35232897 | Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome |
| Q104137153 | Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients |
| Q51422832 | Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. |
| Q45969864 | Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. |
| Q35236769 | Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecut |
| Q37802795 | Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art |
| Q57483947 | Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting |
| Q37326382 | Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting |
| Q28258863 | Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting |
| Q37316977 | Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting |
| Q36920404 | Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant |
| Q45412453 | Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. |
| Q46597375 | Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study |
| Q38132238 | Palonosetron for the prevention of chemotherapy-induced nausea and vomiting |
| Q50442516 | Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients |
| Q37445006 | Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments |
| Q40030462 | Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study |
| Q37104814 | Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting |
| Q55666180 | Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists. |
| Q37013063 | Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting |
| Q41386264 | Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations |
| Q50661502 | SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy |
| Q85708178 | SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013 |
| Q36384479 | Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. |
| Q80268546 | Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials |
| Q37638682 | Tachykinin receptor antagonists in clinical trials |
| Q36900854 | The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting |
| Q36548740 | The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy |
| Q84459254 | Treatment of chemotherapy-induced nausea and vomiting |
Search more.